|
 The 12-week study was testing the efficacy and safety of mirikizumab
in patients with moderate to severe ulcerative colitis, a chronic
inflammatory disease of the colon that leads to ulcers causing
abdominal pain, bloody stools and incontinence.
Mirikizumab met the main goal of reducing colon inflammation and
frequency of stools in patients compared to placebo.
In addition, mirikizumab demonstrated rapid improvement in patient
symptoms as early as four weeks after initiating treatment and met
all secondary goals of the study, the company said.
(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
